Release issued 15th July 2008

Porsolt & Partners Pharmacology announces the appointment of Dr. Mark Duxon as Chief Executive Officer (CEO) of the company. Dr. Duxon will assume his new responsibilities in September 2008.

Dr. Duxon obtained his university training at the University of Nottingham (UK), with a BSc (1st class honours) in molecular biology in 1993 and a PhD in neuropharmacology in 1996. He joined the Merck Neuroscience Research Centre in Terlings Park (UK) as post-doctoral research scientist in 1996. Subsequently, Dr. Duxon took up a position as neuropharmacologist at GSK at the Neuroscience Research Centre in Harlow (UK) in 1998, followed by increasing line management responsibilities in their different drug discovery programs over the ensuing years. After a brief period with Lundbeck (USA), between 2002 and 2003, Dr. Duxon returned to GSK and was posted to Singapore in 2004 to set up and head a new research facility with a € 30 million budget over 5 years. Since April 2006 Dr. Duxon has been CEO of Maccine, a contract research organization (CRO) in Singapore.

Dr. Roger D. Porsolt, founder and currently CEO and President of Porsolt & Partners Pharmacology commented:

"Mark's coming to Porsolt & Partners Pharmacology represents a major milestone in the development of the company. We have achieved great success in the past through our insistence on impeccable service, high quality performance, flexibility in response to client requirements and state-of-the-art science. Our company has now reached a level of complexity where these qualities have to be supplemented by a corresponding increase in the rigor of our financial management, business planning and commercial development, skills that Mark has acquired during his short but intense professional career. Mark is young, dynamic and creative, with impeccable scientific credentials. He has demonstrated his management and commercial skills in a very competitive environment and knows the mechanisms of contract research on the international industrial scene. He is just the man to assume responsibility for the next phases of our development, at a time when I will be taking a step back from active management of the company."

Porsolt & Partners Pharmacology is a privately owned CRO specialized in the preclinical evaluation of novel substances for their potential therapeutic activity (efficacy pharmacology) and adverse effects (safety pharmacology). Concerning the latter, Porsolt & Partners Pharmacology is Grade A certified and fully compliant with the highest international standards of Good Laboratory Practice (GLP). With 85% of its business conducted for clients outside France, Porsolt & Partners Pharmacology is a service provider for the international pharmaceutical industry, and ofits more than 100 clients, 11 are among theworld’s top 20 companies. Porsolt & Partners Pharmacology employs a staff of 72 on two sites, business and scientific administration in Boulogne-Billancourt (Paris region) and the research staff at its 2 500 m² research center in the Mayenne province near to Laval. Porsolt & Partners Pharmacology provides specialized services in a wide variety of therapeutic domains including the central nervous system and pain, the cardiovascular, respiratory, gastro-intestinal, renal and urogenital systems, metabolism and obesity. Porsolt & Partners Pharmacology has obtained an international reputation for its expertise in physio-pathological models and tailored procedures for evaluating substances for the treatment of Alzheimer's disease, epilepsy, neuropathic pain, cardiac insufficiency, hypertension and arrhythmia, eating disorders, and for problems of drug dependence and abuse. To reinforce its panoply of tests, Porsolt & Partners Pharmacology maintains an active internal research program and has published over 100 scientific articles in international journals and books. Its status as a scientific research establishment has been officially recognized by the French Ministry for Research.

With an average growth of over 15% per year over the last 10 years, Porsolt & Partners Pharmacology is currently starting construction of a new 6 000 m² research center on a nearby site, scheduled for completion by the end of 2009.

For further information please contact Dr. Roger D. Porsolt: rporsolt@porsolt.com – www.porsolt.com

(13th May 2009) Argenta Discovery and Porsolt Join Forces to Provide Fully-integrated CNS and Pain Contract Drug Discovery Services

(9th April 2009) Porsolt & Partners Pharmacology announces expansion of Operations and Global Business Development

(16th April 2007) Porsolt & Partners Pharmacology Co-Marketing Agreement with Maccine